THE CASE: An 81-year-old woman with a history of moderate Alzheimer dementia, depression, coronary artery disease, hypertension, and type 2 diabetes mellitus was accompanied to the office by her son for a routine follow-up appointment. She had been taking sertraline for 1 year for treatment of depressive symptoms that included hypersomnia, loss of interest in usual activities, and feelings of hopelessness. The treatment had relieved her symptoms. She had no new complaints, and no changes were made to her regimen.
One week later, the pharmacy reported that the patient's new insurance company would not cover sertraline without prior authorization. Citalopram was substituted.
One month later, the patient's son reported that she had had several episodes of nausea and vomiting during the previous 2 days. These symptoms resolved without intervention. After another 4 weeks, the nausea and vomiting recurred for another 2 days and again resolved without intervention. At a 3-month follow-up appointment, the patient had lost 12 lb, and her son reported that she had neither appetite nor energy. There had been no change in her medications, and the patient's physical and laboratory findings were unrevealing.
Two weeks later, the pharmacy faxed a refill request for sertraline. Further investigation revealed that 4 months previously, the pharmacy had inadvertently added citalopram to sertraline, instead of replacing it. The patient's symptoms resolved when the sertraline was tapered and discontinued.
How can common medication errors in elderly patients be avoided?
Persons aged 65 years or older make up 14% of the population and take more than 30% of prescription drugs.1 Adverse drug reactions are responsible for 5% to 28% of acute geriatric hospital admissions and occur in 35% of community-dwelling elders. The use of multiple medications is associated with a higher likelihood of drug-drug interactions and adverse drug reactions.2 Moreover, there is an increased risk of adverse drug reactions in elderly persons because of pharmacokinetic and pharmacodynamic changes related to aging.3
A recent review concluded that polypharmacy continues to be a significant problem and that little research has been conducted on the methods primary care clinicians use to assess polypharmacy.4
ASSISTANCE FOR CLINICIANSACOVE quality indicators.
One of the largest systematic attempts to prevent adverse drug events in older persons is the Assessing Care of Vulnerable Elders (ACOVE) quality indicators for appropriate medical care, which were developed by Pfizer, Inc, and RAND Health (Table 1 [Part 1, Part 2]).5,6 Studies are under way to determine whether the information contained in the group's Fact Sheets has improved the care that physicians provide for these patients. The methods used to develop the quality indicators included literature review and expert panel discussion.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||